|1.||Van der Linden, Annemie: 1 article (04/2015)|
|2.||Jonckers, Elisabeth: 1 article (04/2015)|
|3.||Guns, Pieter-Jan: 1 article (04/2015)|
|4.||Van Dam, Debby: 1 article (04/2015)|
|5.||Delgado Y Palacios, Rafael: 1 article (04/2015)|
|6.||Shah, Disha: 1 article (04/2015)|
|7.||De Deyn, Peter Paul: 1 article (04/2015)|
|8.||Blockx, Ines: 1 article (04/2015)|
|9.||Verhoye, Marleen: 1 article (04/2015)|
|10.||Walker, Brenda M: 1 article (10/2006)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/1995 - "Safety and tolerability of CI-979 in patients with Alzheimer's disease."
10/01/2006 - "Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer's disease."
05/01/2000 - "Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. "
01/01/1995 - "CI-979 ((E)-1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxaldehyde, O-methyloxime monohydrochloride), a novel muscarinic agonist, is being investigated as a potential treatment for Alzheimer's disease (AD). "
09/01/2002 - "The purpose of this study was to evaluate the effectiveness of activation versus baseline SPECT in detecting the regional cerebral blood flow (rCBF) changes in Alzheimer's disease (AD) patients after milameline (CI979/RU35926) treatment. "
01/28/2003 - "MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD."
01/28/2003 - "The consistency of MRI measurements obtained across sites, and the consistency between the multisite milameline data and that obtained in prior single-site studies, demonstrate the technical feasibility of using structural MRI measures as a surrogate endpoint of disease progression in therapeutic trials. "
|5.||Memory Disorders (Memory Loss)
|2.||Biological Markers (Surrogate Marker)
|6.||Dihydrotachysterol (AT 10)